SLS (SELLAS Life Sciences Group) Cash And Cash Equivalents : $13.89 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Cash And Cash Equivalents?

SELLAS Life Sciences Group's quarterly cash and cash equivalents increased from Jun. 2024 ($9.15 Mil) to Sep. 2024 ($21.03 Mil) but then stayed the same from Sep. 2024 ($21.03 Mil) to Dec. 2024 ($13.89 Mil).

SELLAS Life Sciences Group's annual cash and cash equivalents declined from Dec. 2022 ($17.13 Mil) to Dec. 2023 ($2.53 Mil) but then increased from Dec. 2023 ($2.53 Mil) to Dec. 2024 ($13.89 Mil).

SELLAS Life Sciences Group Cash And Cash Equivalents Historical Data

The historical data trend for SELLAS Life Sciences Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Cash And Cash Equivalents Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

35.30

21.36

17.13

2.53

13.89

SELLAS Life Sciences Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.53	18.42	9.15	21.03	13.89

SELLAS Life Sciences Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SELLAS Life Sciences Group (NAS:SLS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SELLAS Life Sciences Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

RXK3:Germany RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08